Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00627419 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma
A Phase 2 study, sponsored by Infinity Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT00627419 is a Phase 2 study that was terminated before completion, run by Infinity Pharmaceuticals. The registered enrollment target is 1 participants.
The verdict
NCT00627419, a Phase 2 study, was terminated before completion, sponsored by Infinity Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
To evaluate the antitumor activity of IPI-504 in patients with metastatic melanoma.
Interventions
- DRUG IPI-504
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2008-02 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00627419
The ClinicalTrials.gov registry entry for NCT00627419 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Infinity Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IPI-504 is the first listed.
NCT00627419 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00627419 about?
NCT00627419 is a clinical study titled "A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma". To evaluate the antitumor activity of IPI-504 in patients with metastatic melanoma.
What is the current status of trial NCT00627419?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2008-02. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00627419?
The interventions under investigation include: IPI-504 (DRUG).
Who is sponsoring clinical trial NCT00627419?
This trial is sponsored by Infinity Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.